Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company

Sartorius Stedim Biotech Extends Portfolio with Majority Stake in AllPure Technologies

By BiotechDaily International staff writers
Posted on 04 May 2014
Sartorius Stedim Biotech (SSB; Aubagne, France) has signed a contract to acquire the majority stake in the privately owned start-up AllPure Technologies LLC (New Oxford, PA, USA). AllPure Technologies designs, manufactures, and markets innovative aseptic sampling and tube sealing systems for biopharmaceutical and pharmaceutical drug developers and manufacturers; it has been on the market for 4 years, and in 2013 earned revenue of around USD 3 million, with 25 employees. SSB, dedicated to a philosophy of “turning science into solutions,” is a leading global R&D company and provider of cutting-edge equipment, products, and services for the pharmaceutical and biotech industries; it employs approx. 3,300 people, and in 2013 earned sales revenue of EUR 588.4 million.

The takeover extends SSB's portfolio for single-use bioprocessing as AllPure specializes in innovative single-use components for biopharmaceutical applications, such as aseptic sampling techniques. AllPure has launched advanced products to improve operating efficiencies, process reliability, and operator safety. Supported by numerous patent-pending technologies, its products provide quick, reliable, and safe solutions to the shortcomings of current aseptic sampling techniques. AllPure operates in a state-of-the-art facility, and complies with applicable cGMP guidelines.

“AllPure further completes our portfolio with innovative products that help our customers develop and manufacture their pharmaceutical drugs safer and more efficiently. I am really looking forward to working with the AllPure team and to all that we can accomplish together,” said Reinhard Vogt, member of SSB’s Executive Board. "We are excited to leverage Sartorius Stedim’s impressive R&D capabilities so that we can accelerate the launch of new products from AllPure. And SSB’s global reach and industry relationships grant access to considerably more customers, especially in Europe and Asia, which have tremendous potential for AllPure’s products,” said Michael Zumbrum, President of AllPure. SSB and AllPure agreed not to disclose further details of the purchase agreement.

Related Links:

Sartorius Stedim Biotech 
AllPure Technologies 



view channel
Image: Micrograph showing immunofluorescence of skin differentiation markers for basal keratinocytes (Photo courtesy of Dr. Russ Carstens, University of Pennsylvania).

Alternate Splicing Proteins Critically Linked to Skin and Organ Development

Two proteins that regulate alternative splicing in epithelial cells have been linked to the proper development of the skin and protective layers that surround other organs in the body. Two steps are... Read more

Drug Discovery

view channel
Image: Use of catchphrase terms like “breakthrough” and “promising” in public news media presenting new drugs tends to result in incorrect assumptions and conclusions about the meaning and significance of criteria for FDA breakthrough-designated and accelerated-approval drugs (Photo courtesy of Dartmouth Institute).

Words That Inappropriately Enhance Perception of New Drug’s Effectiveness

Researchers have found that using the words “breakthrough” and “promising” in presenting a new drug to the general public often has a dramatic effect on judgment about its effectiveness.... Read more

Lab Technologies

view channel

New Genomic Research Kit Simplifies Exome Studies

An exciting new tool is now available for biotech researchers working in the field of genomic analysis. The human exome is critical to our genetic make-up and is generally accepted as having the greatest influence on how the genetic blueprint is utilized. The exome is defined as all coding exons in the genome and is... Read more


17 Oct 2015 - 21 Oct 2015
25 Oct 2015 - 29 Oct 2015
16 Nov 2015 - 19 Nov 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.